Pharmadrug Inc.
Pharmadrug Inc.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% of Pharmadrug Production GmbH (“Pharmadrug Production”), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug owns 100% Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms as natural based medicines.
Pharmadrug Inc. (PHRX)
SEDAR Information
Information d'entreprise
Capitalisation
Company Officers
Bulletins
2023-1038 – Consolidation - Pharmadrug Inc. (PHRX)
le 20 octobre/October 2023
Pharmadrug Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every seven (7) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 51,518,049 common shares.
The name and symbol will not change.